New Bullous Pemphigoid Research from AstraZeneca Outlined (Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims dataCapsule …): Autoimmune Diseases and Conditions – Bullous Pemphigoid

NewsRx Pharma Business Daily

2023 DEC 07 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Pharma Business Daily -- Investigators publish new report on bullous pemphigoid. According to news originating from Cambridge, United Kingdom, by NewsRx correspondents, research stated, “Real-world data describing the impact of incident bullous pemphigoid (BP) on patients and health care resource utilization (HCRU) are limited. To examine characteristics, treatment patterns, HCRU, and costs for incident BP.”

Financial supporters for this research include Astrazeneca.

Our news editors obtained a quote from the research from AstraZeneca: “Retrospective analysis of 2015 to 2019 US health insurance claims for patients 18 years with an incident BP diagnosis. Patients with BP were matched to those without on demographic and clinical characteristics. Statistics were descriptive. The mean Charlson Comorbidity Index score was higher for patients with BP (n = 1108) than without (n = 4621) at baseline (mean [SD]: 3.3 [2.7] vs 2.8 [2.4]) and during follow-up (5.0 [4.9] vs 3.7 [3.0]). Hypertension, diabetes, skin ulcers, chronic pulmonary disease, dyslipidemia, sleep disorders, and congestive heart failure were higher with BP. Most patients with BP received antibiotics (>80%) and/or corticosteroids (>90%). Hospitalizations were more common (44.0% vs 17.1%) and monthly all-cause health care costs more than double ($3214 vs $1353) in patients with BP than without. Limitations: Diagnoses were based on billing codes. HCRU claims data may not reflect the true number of encounters.”

According to the news editors, the research concluded: “Incident BP is associated with considerable morbidity, HCRU, and costs. More effective, targeted treatments are needed to improve quality of life, while minimizing exposure to systemic corticosteroids.”

For more information on this research see: Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims dataCapsule Summary. JAAD International, 2023,13():117-125. The publisher for JAAD International is Elsevier.

A free version of this journal article is available at https://doi.org/10.1016/j.jdin.2023.04.014.

Our news journalists report that additional information may be obtained by contacting PhD Heide A. Stirnadel-Farrant, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom. Additional authors for this research include PhD Xiao Xu, PharmD Justin Kwiatek, MBBS MBA Priya Jain, MA Juliana Meyers, PhD Sean Candrilli, MD MSCE Daniel Mines, MD MS Catherine J. Datto.